Prospective sampling in intravenously treated oncology patients: Monoclonal AntiBodies

Recruiting

• Conditions: cancer; malignancy; 10027655

• Registration Number: NL-OMON53070
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 2750

Inclusion Criteria

• Age >=18 years
• Able to understand the written information and able to give informed consent
• Planned treatment with (intravenous) monoclonal antibodies

Exclusion Criteria

• Unable to draw blood for study purposes

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>trough level of monoclonal antibodies</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>immunogenicity, characterization of immune cells, tumor response (circulating<br /><br>tumor DNA and germline DNA), hemostatic markers, characteristics of the gut<br /><br>microbiome, immunosenescence </p><br>